<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00062673</url>
  </required_header>
  <id_info>
    <org_study_id>6091</org_study_id>
    <secondary_id>F1J-MC-HMBV</secondary_id>
    <nct_id>NCT00062673</nct_id>
  </id_info>
  <brief_title>Study of Duloxetine in Elderly Patients With Major Depressive Disorder</brief_title>
  <official_title>Duloxetine Versus Placebo in the Treatment of Elderly Patients With Major Depressive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study of the safety and efficacy of duloxetine in elderly patients (greater than 65 years
      old) with major depressive disorder
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Duloxetine 60 mg QD and placebo variable-duration, placebo lead-in period 9 weeks in the
      acute treatment phase
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2003</start_date>
  <completion_date type="Actual">July 2004</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare the efficacy of duloxetine 60 mg QD &amp; placebo on cognition during acute treatment phase in elderly patients using a composite cognitive score derived from the Verbal Learning &amp; Recall Test (VLRT)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>To compare the efficacy of duloxetine 60 mg QD &amp; placebo on cognition during acute treatment phase in elderly patients using a composite cognitive score derived from the Symbol Digit Substitution Test (SDST)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>To compare the efficacy of duloxetine 60 mg QD &amp; placebo on cognition during acute treatment phase in elderly patients using a composite cognitive score derived from 2-Digit Cancellation Test (2DCT)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>To compare the efficacy of duloxetine 60 mg QD &amp; placebo on cognition during acute treatment phase in elderly patients using a composite cognitive score derived from the Letter-Number Sequencing Test (LNST)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To compare the efficacy of treatment with duloxetine 60 mg QD and placebo on depression as measured by the Geriatric Depression Scale (GDS)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare the efficacy of treatment with duloxetine 60 mg QD and placebo on depression as measured by the 17-item Hamilton Depression Rating Scale (HAMD17) total score</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare the efficacy of treatment with duloxetine 60 mg QD and placebo on depression as measured by response and remission rates</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare the efficacy of treatment with duloxetine 60 mg QD and placebo on depression as measured by the Clinical Global Impressions of Severity Scale (CGI Severity) and the HAMD17 subscale scores</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare the efficacy of treatment with duloxetine 60 mg QD and placebo on the painful physical symptoms of depression, as measured by the Visual Analog Scale for pain (VAS)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare the safety of duloxetine 60 mg QD and placebo using information on vital signs, electrocardiograms (ECGs), treatment-emergent adverse events, discontinuation-emergent adverse events, discontinuation rates and laboratory analyses</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the impact of treatment with duloxetine 60 mg QD and placebo on quality of life as measured by the Short-Form (SF-36) Health Survey</measure>
  </secondary_outcome>
  <enrollment>311</enrollment>
  <condition>Depression</condition>
  <condition>Cognition</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duloxetine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  You must be able to visit the doctor's office for clinic visits, tests, and
             procedures.

          -  You must have been diagnosed with major depression, and have had at least one other
             episode in the past.

        Exclusion Criteria:

          -  You have a current or previous major psychiatric disorder other than depression, such
             as bipolar disorder, schizophrenia, or other psychotic disorder.

          -  You have taken a drug within the last 30 days that has not been approved for use by
             governmental authorities.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Middleton</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Puerto Rico</country>
  </removed_countries>
  <link>
    <url>http://www.lillytrials.com</url>
    <description>Lilly Clinical Trial Registry</description>
  </link>
  <verification_date>May 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 10, 2003</study_first_submitted>
  <study_first_submitted_qc>June 11, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2003</study_first_posted>
  <last_update_submitted>May 17, 2007</last_update_submitted>
  <last_update_submitted_qc>May 17, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 21, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Duloxetine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

